key: cord-0824036-ft1vy02y
authors: Karakizlis, Hristos; Nahrgang, Christian; Strecker, Kevin; Chen, Jiangping; Aly, Mostafa; Slanina, Heiko; Schüttler, Christian G.; Esso, Isla; Wolter, Martin; Todorova, Darina; Jessen, Sönke; Adamik, Andrea; Ronco, Claudio; Seeger, Werner; Weimer, Rolf; Sester, Martina; Birk, Horst-Walter; Husain-Syed, Faeq
title: Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis
date: 2022-02-25
journal: Clin Immunol
DOI: 10.1016/j.clim.2022.108961
sha: 5b628b22b331b0a82e632a1e215d76e015feb5c5
doc_id: 824036
cord_uid: ft1vy02y

Patients receiving maintenance dialysis (MD) are vulnerable to COVID-19-related morbidity and mortality. Currently, data on SARS-CoV-2-specific cellular and humoral immunity post-vaccination in this population are scarce. We conducted a prospective single-center study exploring the specific cellular (interferon-γ and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay [CMIA]) at 4 weeks and 6 weeks following a single dose or a complete homologous dual dose SARS-CoV-2 vaccine regimen in 60 MD patients (six with a history of COVID-19). Our results show that MD patients exhibit a high seroconversion rate (91.7%) but the anti-spike IgG antibodies (CMIA) tend to wane rapidly after full immunization. Only 51.7% of the patients developed T cell immune response. High anti-spike IgG antibodies may predict a better cellular immunity. While patients with prior COVID-19 showed the best response after one, SARS-CoV-2-naïve patients may benefit from a third vaccine injection.

Compared with the general population, patients receiving maintenance dialysis (MD) are at increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19) [1] . The poor outcomes have been attributed to their higher comorbidity burden as well as their increased age, immunologically deficient state from kidney failure, or immunosuppressive medications [2] [3] [4] . Compounding these factors, patients undergoing in-center dialysis cannot selfisolate, as they are required to attend their dialysis treatments thrice weekly at a dialysis center, to against the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) spike protein in healthy individuals, which, protect from the risk of subsequent infection [6, 7] . However, whether the results are generalizable to patients with kidney failure is unknown, as the effectiveness of the vaccines has not been explicitly tested in this population due to their common exclusion from SARS-CoV-2 vaccination trials [8, 9] . So far, the limited data available suggest a diminished vaccine response in MD patients [10, 11] . Therefore, there is an urgent need for more data to allow adaptation of the vaccination protocols to achieve adequate antiviral protection for this vulnerable population, if needed.

The main objective of the present study was to examine the humoral and cellular immunogenicity and reactogenicity of a homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimen in patients receiving MD.

This prospective, single-center cohort study included patients aged ≥18 years receiving thriceweekly in-center dialysis (hemodialysis or peritoneal dialysis) at the Patienten-Heimversorgung outpatient dialysis center at University Hospital Giessen and Marburg, Giessen, Germany. At the time of enrollment, the dialysis center served 84 hemodialysis patients and 5 peritoneal dialysis patients. Patients were enrolled if they had: i) received a homologous mRNA-based or a single-dose or homologous dual dose vector-based vaccine regimen (with or without history of , and days. Local and systemic adverse events after the first and second dose were self-reported using a standardized questionnaire.

The study was approved by the local human research ethics committee (AZ 126/21) and complied with the tenets of the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrollment in the study.

Vaccine-induced SARS-CoV-2-specific T cells were quantified from citrated whole blood using a multicolor FluoroSpot Immune assay kit (CoV-iSpot, FluoroSpot Assay, AID/GenID, Straßberg, Germany) that detects functional T cells and an interferon (IFN)-γ and interleukin (IL)-2 reaction specifically against SARS-CoV-2. The results were evaluated by calculating the ratio of the antigen specific reaction and negative control (NC) (stimulation index, SI). Any antigen-specific FluoroSpot test with an SI of ≤2 (NC > 2) or ≤5 (NC < 2), depending on the background stimulation, was considered negative when assessed quantitatively. For NC <2 a stimulation index of > 5 -< 7 was considered borderline and a SI ≥ 7 was considered positive, whereas for NC ≥2 a stimulation index of > 2 -≤ 3 was considered borderline and a SI > 3 was considered positive. A reactive response was considered when at least one timepoint showed a reactive pattern and the other timepoint was reactive or borderline or negative or invalid. A borderline response was considered when one timepoint was borderline and the other timepoint was borderline or negative or invalid. A negative response was considered when one timepoint was negative and the other timepoint was negative or invalid. Only when both timepoints were invalid the response was considered as invalid. GenID performed all FluoroSpot tests, blinded to the clinical data. The

Supplementary Material provides a detailed description of the ELISpot method.

J o u r n a l P r e -p r o o f Journal Pre-proof

SARS-CoV-2-specific antibodies were quantified using plasma from citrated whole blood samples using an immunoglobulin G (IgG) assay coated with a recombinant receptor-binding domain of the SARS-CoV-2 spike protein antigen using an in-house dot plot array by GenID, blinded to the clinical data. Antibody levels are expressed in % intensity of gray scale, ranging from 0 to 100 percent black, with an intensity of >16% considered positive and ≤16% considered negative, respectively. In addition, SARS-CoV-2-specific antibodies from serum samples against the spike protein and nucleocapsid protein were performed by the Institute of Medical Virology (Giessen, Germany) using antibody chemiluminescent microparticle immunoassay (CMIA; Anti-S AdviseDx SARS-CoV-2 IgG II and Anti-N Abbott Architect SARS-CoV-2 IgG, Abbott, Chicago, IL, USA).

The anti-N array (measured in S/CO) was used to detect a previous infection. Anti-S levels after infection or vaccination were expressed as AU (arbitrary unit)/ml with levels >50AU/ml defined as positive and ≤50 AU/ml as negative.

All other blood samples were analyzed at the local Institute of Laboratory Medicine at University Hospital Giessen and Marburg, Giessen, where they were processed within 30 min of collection and centrifuged for 10 min at 3000 ×g. Serum creatinine was measured by a photometric-enzymatic method on an ADVIA Chemistry XPT analyzer (enzymatic creatinine; Siemens Healthineers, Erlangen, Germany), with calibration to reference measurements for isotope dilution mass spectrometry. Ferritin was measured by chemiluminescent immunoassay (CLIA) on a Centaur XPT analyzer (Siemens Healthineers). Soluble IL-2 receptor and IL-6 were determined on a Siemens

Immulite 1000 system with Siemens reagents.

Descriptive statistics are expressed as the median [interquartile range] for numeric variables and as n (%) for categorical variables. Differences between two independent groups were tested with the Mann-Whitney test or independent t-test according to the variables' distribution normality.

Categorical variables were tested with the chi-square test or Fisher's exact test. Paired ordinal data were compared using the Wilcoxon signed-rank test; paired nominal data were compared using the McNemar test. Univariate and multivariate logistic regression analyses with backwards elimination were conducted with IL-2 or IFN-γ ELISpot test reactivity at either T1 or T2 as a dependent variable. Independent variables with significant associations in the univariate analysis (p<0.1) were further included in the multivariate regression analysis. The statistical analysis was performed with SPSS Statistics 26 (IBM, Ehningen, Germany). P-values <0.05 were considered significant.

A total of 60 patients were enrolled in this study. All patients had either received a single dose or a dual-dose homologous vaccine regimen. Fifty-one patients had received mRNA-based vaccines (BNT162b2, n = 49; mRNA-1273, n = 2); nine patients had received vector-based vaccines (ChAdOx1 nCoV-19, n = 6; Ad26.COV2.S, n = 3). Six patients had received a booster vaccination 6 months after SARS-CoV-2 infection. Table 1 shows the characteristics of the study population; the median age of the population was 65.4 years; 63.3% were male; 35% had diabetes mellitus; 90% had hypertension, and 50% had coronary heart disease. The main causes of kidney failure were glomerulonephritis (21.7%), diabetes (20%), and nephrosclerosis (16.7%) . No demographic differences in the demographic data were observed between patients receiving mRNA-based vaccines vs. vector-based vaccines. The median length of time on dialysis was 33 months.

Hemodialysis was the dialysis modality adopted by 88.3% of the study population. No difference J o u r n a l P r e -p r o o f Journal Pre-proof was observed in key laboratory parameters between T1 and T2 (Supplementary Material Table S1).

A total of 50 and 58 patient samples were analyzed at T1 and T2, respectively.

We first analyzed all patient samples irrespective of the vaccine type and history of COVID-19. The majority of patients showed no reactivity in the IL-2 and IFN-γ ELISpot assays at T1 (42.0% and 74.0%, respectively) and T2 (36.2% and 58.6%, respectively), while there was a reactive pattern in the IL-2 and IFN-γ ELISpot assays at T1 in 36.0% and 22.0% of the patients, respectively, and at T2 in 25.9% and 24.1% of the patients, respectively ( Figure 1A and B ). An IL-2 and/or IFN-γ reactivity in at least one time point was observed in 51.7% of patients ( Figure 1C ), whereas a nonresponse in all samples was observed in 33.3% of the patients. Borderline reactivities and invalid test results were observed in 10.0% and 5.0% of patients, respectively ( Figure 1A ). There was no difference in the median IL-2 and IFN-γ reactivities between both time points (p = 0.93 and p = 0.85, respectively; Table 2 ).

In the Abbott array, 89.8% of patients had SARS-CoV-2 anti-spike IgG antibodies above the detection limit (IgG >50 AU/mL at T1 and remained positive at T2, whereas 8.6% of patients were classified as negative (IgG ≤ 50 AU/mL) at both time points ( Figure 1E ). However, the median SARS-CoV-2 anti-spike IgG antibody levels were significantly lower at T2 compared to T1 (2240 [756-7687] AU/mL vs. 3517 [1070-11164] AU/mL; p < 0.001; Table 2 ). In contrast, when using the GenID assay, the median percentage of median SARS-CoV-2 anti-spike IgG antibodies were A positive test result in at least one assay at either T1 or T2 was observed in 91.7% of patients, whereas 8.3% were consistently negative in both assays ( Figure 1D ).

Overall, five patients (8.3%) did not generate anti-spike IgG antibodies. Four of these patients showed no cellular immune response and one patient showed a positive cellular immune response at time T1 but a negative one at time T2 (Table S2 in 

Patients showing IL-2 producing T cells had higher levels of SARS-CoV-2 anti-spike IgG at both timepoints in both the Abbott array (T1, p = 0.024; T2, p = 0.001) and the GenID assay (T1, p = 0.024; T2, p = 0.007) compared to those who did not show any IL-2 reactivity. We excluded patients with borderline results from the comparison. Likewise, we found higher levels of SARS-CoV-2 anti-spike IgG at both timepoints in both the Abbott array (T1, p = 0.002; T2, p > 0.001) and

GenID assay (T1, p = 0.019; T2, p = 0.01) in patients with IFN-γ ELISpot positive reactivity compared to the non-reactive patients.

Multivariate logistic regression analysis showed that among the variables included, the independently associated with SARS-CoV-2 IgG levels as measured with the Abbott array at both timepoints. We did not find other confounders that had an effect on ELISpot reactivity (Table 3) .

The Abbott assay showed that patients with previous SARS-CoV-2 infection who had received a booster vaccination exhibited higher SARS-CoV-2 anti-spike IgG concentrations at both timepoints when compared to SARS-CoV-2-naïve patients with full vaccination (T1 and T2, p < 0.001; Table   4 and Figure 2 ). Also, patients with previous SARS-CoV-2 infection showed a higher SI in the IL-2 ELISpot at T1 (p = 0.004) but not at T2 (p = 0.07). Such patients also had a higher SI in the IFN-γ ELISpot at both timepoints (T1 and T2, p < 0.001). Patients with history of COVID had significantly higher levels of response in the GenID assay (91.5% vs. 76%, p=0.04) at time T1, but not at time T2 (92% vs. 83%, p=0.15) ( Table 4 ). The vaccination regimen in the infection-naïve patients did not affect the vaccination response compared to the group with history of COVID-19 (Table S3 and S4 in the Supplementary Material). Also, the dialysis regime (hemodialysis vs. peritoneal dialysis) had no effect on the immunity response (data not shown). However, it should be noted that there was only a small number of patients receiving a vector-based vaccination regimen and peritoneal dialysis and, thus, the groups may be underpowered.

Adverse events were reported by 28 (46.7%) and 22 (43.1%) patients after the first and second dose, respectively (Supplementary Material Table S5 ). The onset of adverse events was mostly reported within 3 days after vaccination (after the first dose, 89.3% of patients; after the second dose, 100% of patients). The main reported adverse events were pain and swelling or redness at the injection site (after the first dose, 31.6%; after the second dose, 27.4%) and tiredness/fatigue (after the first dose, 16.7%; after the second dose, 23.5%). No association was observed between the reported reactogenicity and the immune response (data not shown).

Journal Pre-proof 4. Discussion

We prospectively quantified the humoral and cellular immune response at both 4 weeks and 6 weeks after full vaccination in patients receiving MD. Most patients (91.7%) had detectable SARS-CoV-2 anti-spike IgG antibodies in at least one time point. However, the median SARS-CoV-2 anti-spike IgG antibody levels measured with the Abbott assay were significantly lower at 6 weeks post-vaccination compared to 4 weeks, indicating that although a full vaccination regimen was sufficient for inducing SARS-CoV-2-specific antibodies, the antibody levels tended to decrease rapidly. In addition, although only 51.7% of patients were reactive in the SARS-CoV-2-specific T cell activation ELISpot assays, there were no detectable differences in the IL-2 or IFN-γ reactivities between both time points, suggesting the short-term stability of cellular immunity compared to humoral immunity after full vaccination. Finally, patients receiving a booster vaccination after SARS-CoV-2 infection showed both better humoral and cellular immunity compared to SARS-CoV-2-naïve patients with full vaccination, whereas patients with immunosuppressive therapy developed almost no detectable humoral or cellular immunity.

The observed high humoral immune response to the SARS-CoV-2 spike protein is similar to a recent vaccine trial involving healthy adults [14] . Some studies on the humoral response in IL-2, SI 2.4 [1.5-4.5] (n = 33)

1.6 [1.0-4.7] (n = 33) 0.93 IFN-γ, SI 3 [1] [2] [3] [4] [5] (n = 43)

3 [1] [2] [3] [4] [5] [6] [7] (n = 43) a Thirty-nine cases were included in the logistic regression analysis due to missing cases.

b Thirty-six cases were included in the logistic regression analysis due to missing cases. Bolded p-values denote statistical significance at the p < 0.05 level.

a Forty-eight cases were included in the logistic regression analysis due to missing cases.

b Refers to indicator.

c Refers to variables included in the multivariate logistic regression analysis with backward elimination.

95% CI, 95% confidence interval; COVID-19, coronavirus disease 2019; CRP, C-reactive protein;

IL-6, interleukin-6; OR, odds ratio; PD, peritoneal dialysis; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; T1, timepoint 1; T2, timepoint 2. 

the Northwell Nephrology, Outcomes of patients with endstage kidney disease hospitalized with COVID-19

The current and future landscape of dialysis

Antibody Status, Disease History, and Incidence of SARS-CoV-2 Infection Among Patients on Chronic Dialysis

Aspects of immune dysfunction in end-stage renal disease

COVID-19 vaccines

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease

Systematic Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients with Chronic Kidney Disease

Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis

Canadian Society of Nephrology Work Group on Adequacy of Peritoneal, Clinical Practice Guidelines and Recommendations on Peritoneal Dialysis Adequacy

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in hemodialysis patients: a multicenter study

Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients

Spike and neutralizing antibodies response to COVID-19 vaccination in haemodialysis patients

Early Humoral Responses of Hemodialysis Patients after COVID-19 Vaccination with BNT162b2

Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis

Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost

Lessons for COVID-19 Immunity from Other Coronavirus Infections

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

Impaired immune responses and antigen-specific memory CD4+ T cells in hemodialysis patients

Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy

A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization

Weak correlation between antibody titers and neutralizing activity in sera from SARS-CoV-2 infected subjects

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls

Functional signatures in antiviral T-cell immunity for monitoring virusassociated diseases

SARS-CoV-2 anti-spike IgG antibodies at T1, % (GenID)

COVID-19, coronavirus disease

SARS-CoV-2, severe acute respiratory syndrome coronavirus type-2

Vaccine-induced SARS-CoV-2-specific IL-2 (A) and IFN-γ (B) and IL-2 and/or IFNγ (C)-producing T cells and SARS-CoV-2 anti-spike IgG antibodies as determined using the Abbott assay (D)